Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.

ABSTRACT:

Background

Semaglutide, liraglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists that are effective for weight reduction. Recent reports of patients experiencing suicidal thoughts and other psychiatric adverse events while using GLP-1 agonists have raised concerns about the potential risk of self-harm and led the European Medicines Agency to investigate these medications.

Aim

To identify and analyse the psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide.

Method

All individual case safety reports for semaglutide, liraglutide, and tirzepatide reported to the EudraVigilance database from 01/01/2021 to 30/05/2023 were analysed. Descriptive statistics were used to explore study population characteristics.

Results

SUBMITTER: Tobaiqy M 

PROVIDER: S-EPMC10960895 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature